Carisma Therapeutics initiated with a Buy at EF Hutton

EF Hutton initiated coverage of Carisma Therapeutics (CARM) with a Buy rating and $24 price target Carisma may be the company that creates the first solid tumor CAR therapy using macrophages, the analyst tells investors in a research note. The firm says the company is also working with Moderna to develop an in-vivo CAR-M therapeutic. Success can potentially transform the CAR landscape as we know it today, contends EF.